- Home
- RITM vs BBIO Comparison
RITM vs BBIO Comparison
Compare RITM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITM
- BBIO
- Stock Information
- Founded
- RITM 2011
- BBIO 2015
- Country
- RITM United States
- BBIO United States
- Employees
- RITM N/A
- BBIO N/A
- Industry
- RITM Real Estate Investment Trusts
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RITM Real Estate
- BBIO Health Care
- Exchange
- RITM Nasdaq
- BBIO Nasdaq
- Market Cap
- RITM 5.5B
- BBIO 4.9B
- IPO Year
- RITM N/A
- BBIO 2019
- Fundamental
- Price
- RITM $10.73
- BBIO $23.72
- Analyst Decision
- RITM Strong Buy
- BBIO Strong Buy
- Analyst Count
- RITM 10
- BBIO 13
- Target Price
- RITM $12.65
- BBIO $46.92
- AVG Volume (30 Days)
- RITM 4.4M
- BBIO 1.6M
- Earning Date
- RITM 10-29-2024
- BBIO 11-12-2024
- Dividend Yield
- RITM 9.33%
- BBIO N/A
- EPS Growth
- RITM N/A
- BBIO N/A
- EPS
- RITM 0.99
- BBIO N/A
- Revenue
- RITM $3,006,456,000.00
- BBIO $217,765,000.00
- Revenue This Year
- RITM N/A
- BBIO $3,690.39
- Revenue Next Year
- RITM $4.33
- BBIO N/A
- P/E Ratio
- RITM $10.86
- BBIO N/A
- Revenue Growth
- RITM 1.78
- BBIO 2209.77
- 52 Week Low
- RITM $9.97
- BBIO $21.62
- 52 Week High
- RITM $12.02
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- RITM 49.14
- BBIO 41.49
- Support Level
- RITM $10.68
- BBIO $24.09
- Resistance Level
- RITM $10.89
- BBIO $27.57
- Average True Range (ATR)
- RITM 0.18
- BBIO 1.39
- MACD
- RITM 0.05
- BBIO -0.09
- Stochastic Oscillator
- RITM 68.00
- BBIO 17.20
About RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company's mission is to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Rithm Capital's investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.